Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10308344 | 0.82 | KDM4E (0.33) | HMGCRCHRM1TBXA2RADRA1APIK3CD | |
| SCHEMBL7917694 | 0.80 | PIK3CD (0.46) | HMGCRCHRM1TBXA2RADRA1APIK3CD | |
| SCHEMBL10212340 | 0.78 | PIK3CD (0.31) | HMGCRCHRM1TBXA2RADRA1APIK3CD | |
| SCHEMBL22253948 | 0.78 | PIK3CD (0.31) | HMGCRCHRM1TBXA2RADRA1APIK3CD | |
| SCHEMBL18264641 | 0.78 | CYP2C19 (0.32) | HMGCRCHRM1TBXA2RADRA1APIK3CD | |
| SCHEMBL10212341 | 0.78 | PIK3CD (0.31) | HMGCRCHRM1TBXA2RADRA1APIK3CD | |
| SCHEMBL19059089 | 0.78 | PIK3CD (0.31) | HMGCRCHRM1TBXA2RADRA1APIK3CD | |
| SCHEMBL10212337 | 0.78 | PIK3CD (0.31) | HMGCRCHRM1TBXA2RADRA1APIK3CD | |
| SCHEMBL17449479 | 0.78 | PIK3CD (0.35) | HMGCRCHRM1TBXA2RADRA1APIK3CD | |
| SCHEMBL11161149 | 0.76 | PIK3CD (0.39) | HMGCRCHRM1TBXA2RADRA1APIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | NOVARTIS AG (CH) | 2024-02-27 | — | — | US | disclosed |
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | CORNELL UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230257347-A1 | ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230144824-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2023-05-11 | — | — | US | disclosed |
| US-10030029-B2 | Imidazole derivative used as antiviral agent and use thereof in preparation of medicament | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. (CN) | 2018-07-24 | — | — | US | disclosed |
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2018-07-12 | — | — | US | disclosed |
| US-9988420-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2018-06-05 | — | — | US | disclosed |
| US-9981972-B2 | N-hydroxy bicyclic hydantoin carbamates as tools for identification of serine hydrolase targets | ABIDE THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9938323-B2 | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase | NOVARTIS AG (CH) | 2018-04-10 | — | — | US | disclosed |
| US-RE46757-E1 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2018-03-20 | — | — | US | disclosed |
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20070287713-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-7279485-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-09 | — | — | US | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-7273876-B2 | Substituted bicylic thiophene derivatives, compositions containing such compounds and methods of use | MERCK & CO., INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070117827-A1 | Compositions for affecting weight loss | U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2007-05-24 | — | — | US | disclosed |
| US-20070117827-A1 | Compositions for affecting weight loss | U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2007-05-24 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117827-A1 | Compositions for affecting weight loss | MC4R, MC3R, MC5R | HMGCR 1221/4885CHRM1 255/4885TBXA2R 1480/4885 |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | HMGCR 3085/4885CHRM1 4864/4885TBXA2R 3960/4885 |
| US-20070287713-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | PYM1, GPR119, GLP1R | HMGCR 1147/4885CHRM1 42/4885TBXA2R 3633/4885 |
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | PSMB5, PSMB1, PSMB3 | HMGCR 2594/4885CHRM1 1644/4885TBXA2R 2867/4885 |
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | CFTR, OPRK1, CHRM3 | HMGCR 4344/4885CHRM1 6/4885TBXA2R 1895/4885 |
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, KAT2A | HMGCR 692/4885CHRM1 1068/4885TBXA2R 259/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | HMGCR 3085/4885CHRM1 4864/4885TBXA2R 3960/4885 |
| US-20230257347-A1 | ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | HTR6, TPH2, TPH1 | HMGCR 3092/4885CHRM1 390/4885TBXA2R 1403/4885 |
| US-20230144824-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | TLR7, TLR9, TLR1 | HMGCR 4569/4885CHRM1 1784/4885TBXA2R 119/4885 |
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | JAK2, NTRK2, NTRK3 | HMGCR 4458/4885CHRM1 3986/4885TBXA2R 1668/4885 |
| US-10030029-B2 | Imidazole derivative used as antiviral agent and use thereof in preparation of medicament | MAVS, ZC3HAV1, SARS1 | HMGCR 1448/4885CHRM1 3552/4885TBXA2R 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.